Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,601–3,700 of 15,747
Giuffrida, G., Condorelli, A., Giorgio, M. A. D., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279535 · Cited by 29
“Immune-mediated TTP was not mentioned among the adverse events in the pivotal study leading to the approval of this vaccine.(7) Given the immune origin of the TTP and the short latency period between the COVID19 vaccine and disease onset, a hypothesized temporal association is plausible.”
BackgroundSecret messengers: Extracellular RNA communication in the immune system
Nation, G. K., Saffold, C. E., & Pua, H. H. (2021) · Immunological Reviews · doi:10.1111/imr.13027 · Cited by 29
Ring, J., Worm, M., Wollenberg, A., Thyssen, J. P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T. R. M., de Bruin-Weller, M. S., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17237 · Cited by 30
Xu, C., Wang, A., Geng, K., Honnen, W. J., Wang, X., Bruiners, N., Singh, S., Ferrara, F., D’Angelo, S., Bradbury, A. M., et al. (2021) · Viruses · doi:10.3390/v13060953 · Cited by 30
“Although effective SARS-CoV-2 vaccines are available [7,8], potent anti-viral agents are still not clinically available to suppress infection in SARS-CoV-2-infected patients.”
BackgroundSARS-CoV-2 and male infertility: from short- to long-term impacts
Dai, P., Qiao, F., Chen, Y.-S. E., Chan, D. Y. L., Yim, H. C. H., Fok, K. L., & Chen, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02055-x · Cited by 31
Dhumal, S. B., Patil, A., More, A. N., Kamtalwar, S., Joshi, A. D., Gokarn, A. G., Mirgh, S. P., Thatikonda, P., Bhat, P., Murthy, V., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.037 · Cited by 27
Camacho-Moll, M. E., Salinas-Martínez, A. M., Cisneros, B. T., Onofre, J. I. G., Floriano, G. N., & de León, M. B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.834744 · Cited by 31
“An ongoing multinational placebo-controlled clinical trial reported 27% (34), but surveys with self-reported symptoms showed figures between 80 and 92% (21, 22, 35).”
BackgroundBotton, J., Dray‐Spira, R., Baricault, B., Drouin, J., Bertrand, M., Jabagi, M.-J., Weill, A., & Zureik, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.009 · Cited by 29
SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions
Timmers, L. F. S. M., Peixoto, J. V., Ducati, R. G., Bachega, J. F. R., Pereira, L. D. M., Caceres, R. A., Majolo, F., da Silva, G. L., Anton, D. B., Dellagostin, O. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91585-6 · Cited by 31
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Kurup, D., Malherbe, D. C., Wirblich, C., Lambert, R., Ronk, A. J., Diba, L. Z., Bukreyev, A. A., & Schnell, M. J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009383 · Cited by 30
Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV
Griffin, D. W. J., Mangalore, R. P., Hoy, J., & McMahon, J. H. (2023) · AIDS · doi:10.1097/qad.0000000000003579 · Cited by 28
A Vaccination Strategy for Ontario COVID-19 Hotspots and Essential Workers
Mishra, S., Stall, N. M., Ma, H., Odutayo, A., Kwong, J. C., Allen, U., Brown, K. A., Bogoch, I. I., Erman, A., Huynh, T., et al. (2021) · doi:10.47326/ocsat.2021.02.26.1.0 · Cited by 36
Arab nations first to approve Chinese COVID vaccine — despite lack of public data
Cyranoski, D. (2020) · Nature · doi:10.1038/d41586-020-03563-z · Cited by 29
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2
Castonguay, N., Zhang, W., & Langlois, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676314 · Cited by 29
Yendewa, S. A., Ghazzawi, M., James, P., Smith, M. E., Massaquoi, S. P. E., Babawo, L. S., Deen, G. F., Russell, J. B., Samai, M. H., Sahr, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10050757 · Cited by 28
Mehta, S. H., Clipman, S. J., Wesolowski, A., & Solomon, S. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-96779-6 · Cited by 40
Immune Cells, Gut Microbiota, and Vaccines: A Gender Perspective
Rio, P., Caldarelli, M., Chiantore, M., Ocarino, F., Candelli, M., Gasbarrini, A., Gambassi, G., & Cianci, R. (2024) · Cells · doi:10.3390/cells13060526 · Cited by 34
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
“: BNT162b2 (Pfizer) (Polack et al., 2020), mRNA-1273 (Moderna)”
BackgroundInfluentialCollaborative:, T. O., Green, A. C. A., Curtis, H. J., Hulme, W. J., Williamson, E., McDonald, H. I., Bhaskaran, K., Rentsch, C. T., Schultze, A., MacKenna, B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02422-0 · Cited by 32
Hanly, M., Churches, T., Fitzgerald, O., Caterson, I. D., MacIntyre, C. R., & Jorm, L. R. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08447-8 · Cited by 33
“2 Assessment exponential 2 + exp(1) 2.”
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination
Bando, T., Takei, R., Mutoh, Y., Sasano, H., Yamano, Y., Yokoyama, T., Matsuda, T., Kataoka, K., Kimura, T., & Kondoh, Y. (2022) · European Respiratory Journal · doi:10.1183/13993003.02806-2021 · Cited by 27
Talele, G., Vaidhya, S., Chowdhary, A. S., et al. (2021) · Homeopathy · doi:10.1055/s-0041-1735235 · Cited by 28
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28
“Vac-cines currently available in the United States provide robust protection against severe COVID-19 outcomes including hospitalization and death (2–4).”
Dey, D., Singh, S., Khan, S., Martin, M. F., Schnicker, N., Gakhar, L., Pierce, B. G., & Hasan, S. S. (2022) · Communications Biology · doi:10.1038/s42003-022-03063-y · Cited by 28
Verma, A. K., Kumar, I., Singh, P. K., Ansari, M. S., Singh, H. A., Sonkar, S., Prakash, A., Ojha, R., & Shukla, R. C. (2022) · European Radiology · doi:10.1007/s00330-021-08475-8 · Cited by 31
Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients
Paal, M., Arend, F. M., Lau, T., Hasmann, S. E., Soreth-Rieke, D., Sorodoc-Otto, J., Beuthien, W., Krappe, J., Toepfer, M., von Gersdorff, G., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab127 · Cited by 32
Risk of autoimmune skin and connective tissue disorders after mRNA-based COVID-19 vaccination
Ju, H. J., Lee, J. Y., Han, J. H., Lee, J. H., Bae, J. M., & Lee, S. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.05.017 · Cited by 31
“Clinical trials of mRNA-based COVID-19 vaccines have shown that they are effective and have acceptable safety profiles.(11,12) Despite the numerous contributions of vaccines to public health, their role in triggering autoimmune diseases has been controversial for decades.”
Cordtz, R., Kristensen, S., Westermann, R., Duch, K. S., Pearce, F., Lindhardsen, J., Torp-Pedersen, C. T., Andersen, M. P., & Dreyer, L. (2022) · Rheumatology · doi:10.1093/rheumatology/keac241 · Cited by 29
Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
Andrew, M. K., Schmader, K. E., Rockwood, K. J., Clarke, B., & McElhaney, J. E. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295522 · Cited by 30
Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 38
“30,31 In the retina specifically, previous studies examined the delivery of mCherry and luciferase mRNA LNP to the mouse retina, with expression in RPE and Müller glia cells over 4 to 96 hours post-subretinal injection.”
BackgroundVaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein, S., Xia, Z., Lee, A., Dahl, M., Edwards, K. R., Levit, E., Longbrake, E. E., Perrone, C. M., Kavak, K. S., Weinstock‐Guttman, B., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103433 · Cited by 28
“Notably, there was no new side effect signal for either the NID or control group when compared to published SARS-CoV-2 vaccine trials (Baden et al., 2020; Folegatti et al., 2020; Polack et al., 2020; Voysey et al., 2021).”
ResultAdvances in mRNA-based drug discovery in cancer immunotherapy
Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 29
“cines: the mRNA COVID-19 vaccines [19,20].”
Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report
Lemoine, C., Padilla, C., Krampe, N. A., et al. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06126-x · Cited by 28
mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines
Zhivaki, D., Gosselin, E. A., Sengupta, D., Concepcion, H. A., Arinze, C., Chow, J., Nikiforov, A., Komoroski, V., MacFarlane, C., Sullivan, C., et al. (2023) · mBio · doi:10.1128/mbio.02506-23 · Cited by 32
“The speed of their production and their efficacy in preventing serious COVID-19 infections have increased interest in the use of nucleic acids as antigen-delivery vehicles (5).”
BackgroundTakeuchi, Y., Iwagami, M., Ono, S., Michihata, N., Uemura, K., & Yasunaga, H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.088 · Cited by 30
“Randomised clinical trials showed the high efficacy of the vaccines and low incidence of severe adverse events owing to their administration [2, 3].”
BackgroundVandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27
Strategies for Vaccine Prioritization and Mass Dispensing
Lee, E. K., Li, Z. L., Liu, Y. K., & LeDuc, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050506 · Cited by 32
“Percentage of vaccine efficacy • Probability of full immunity • Probability of partial immunity • Probability of no immunity (behave like any susceptible individuals) 70–90% 70–90% 5–25% 5% [69,70]”
BackgroundIqbal, S. M., Rosen, A. M., Edwards, D. K., Bolio, A., Larson, H. J., Servin, M., Rudowitz, M., Carfí, A., & Ceddia, F. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1429265 · Cited by 31
“%) and a favorable risk– benefit profile (36, 37).”
BackgroundTargeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice
Çimen, İ., Natarelli, L., Kichi, Z. A., Henderson, J. M., Farina, F. M., Briem, E., Aslani, M., Megens, R. T. A., Jansen, Y. J. F. M., Mann-Fallenbuchel, E., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf3357 · Cited by 32
Witkowski, W., Gerlo, S., Smet, E. D., Wejda, M., Acar, D. D., Callens, S. F. J., Heytens, S., Padalko, E. Y., Vercruysse, H., Cools, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10020260 · Cited by 28
Song, I., & Lee, S. H. (2023) · BMC Public Health · doi:10.1186/s12889-023-15182-0 · Cited by 34
“This difference may have occurred in part because this present study used data collected in late 2021 when clinical trial data were available [31], and in another part because safety was a greater concern than a lack of efficacy as a reason for COVID-19 vaccine hesitancy [24].”
BackgroundResultDubey, A., Kotnala, G., Mandal, T. K., Sonkar, S. C., Singh, V. K., Guru, S. A., Bansal, A., Irungbam, M., Husain, F., Goswami, B., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27029 · Cited by 29
(2021) · doi:10.1101/2021.04.20.21254636 · Cited by 28
“There has been a very rapid development of vaccines against SARS-CoV-2 and mass vaccination campaigns have been launched worldwide [1, 2].”
BackgroundOlmedillas, E., Mann, C. J., Peng, W., Wang, Y.-T., Díaz-Avalos, R., Bedinger, D., Valentine, K. M., Shafee, N., Schendel, S. L., Yuan, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.441046 · Cited by 25
“Vaccines currently deployed in the United States use a derivative of the prototypical, first-generation “S-2P” spike design (Pallesen et al. 2017), which contains two proline substitutions at positions 986 and 987 (Polack et al. 2020; Bos et al. 2020; Corbett et al. 2020; Wrapp et al. 2020).”
BackgroundYadav, S., Todd, A., Patel, K., Tabriz, A. A., Nguyen, O. T., Turner, K. L., & Hong, Y. (2022) · Clinical Medicine · doi:10.7861/clinmed.2022-0107 · Cited by 32
Seija, M., Rammauro, F., Santiago, J. L., Orihuela, N., Zulberti, C., Machado, D., Recalde, C., Noboa, J., Frantchez, V., Astesiano, R., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab291 · Cited by 31
“In Uruguay, the Ministry of Public Health approved inactivated SARS-CoV-2 (CoronaVac®, Sinovac Biotech Ltd) and BNT162b2 mRNA (Pfizer/BioNTech) vaccines for emergency use [28, 29].”
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue, Y., Hou, X., Zhong, Y., Zhang, Y., Du, S., Kang, D. D., Wang, L., Wang, C., Li, H., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57149-2 · Cited by 36
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy
Rodríguez, N. O., Berasategui, M. T. A., Caballer, B. D. L. H., & Santiago, A. V. (2021) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0665 · Cited by 26
Tarkowski, M., de Jager, W., Schiuma, M., Covizzi, A., Lai, A., Gabrieli, A., Corbellino, M., Bergna, A., Ventura, C. D., Galli, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793191 · Cited by 31
“org 2 7 days after receiving the second vaccine dose, with an acceptable safety profile (20).”
BackgroundWaddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
“For example, clinically, it has been used to deliver mRNA as a vaccine, 45,46 antisense RNA to treat spinal muscular atrophy 47 and, in separate studies, to treat hereditary transthyr-etin amyloidosis by delivery of siRNA 48 and gene editing machinery (template plus Cas9 mRNA).”
MethodPericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting
Yap, J. J. L., Tham, M. Y., Poh, J. W. W., Toh, D., Chan, C. L., Lim, T. W., Lim, S. L., Chia, Y. W., Lim, Y. T., Choo, J. T. L., et al. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021425 · Cited by 31
Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
Mohan, A., Iyer, V. A., Kumar, D., Batra, L., & Dahiya, P. (2023) · Life · doi:10.3390/life13112121 · Cited by 59
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
Wang, Z., Jacobus, E. J., Stirling, D. C., Krumm, S. A., Flight, K. E., Cunliffe, R. F., Mottl, J., Singh, C., Mosscrop, L. G., Santiago, L. A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102045 · Cited by 31
Self-citationSuhandynata, R. T., Bevins, N., Tran, J. T., Huang, D., Hoffman, M. A., Lund, K., Kelner, M. J., McLawhon, R. W., Gonias, S. L., Nemazee, D. A., et al. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab080 · Cited by 30
“This panel detects Adenovirus (A-F), Coronavirus (229E, HKU1, NL63, OC42), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, B and C, Influenza 2009 H1N1, Parainfluenza (1-4), Respiratory Syncytial Virus (A and B), Chlamydia pneumoniae and Mycoplasma pneumoniae.”
COVID-19 im Alter – Die geriatrische Perspektive
Wirth, R., Becker, C., Djukic, M., Drebenstedt, C., Heppner, H. J., Jacobs, A. H., Meisel, M., Michels, G., Nau, R., Pantel, J., et al. (2021) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-021-01864-0 · Cited by 30
Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination
Schäfer, I., Oltrogge, J. H., Nestoriuc, Y., Warren, C. V., Brassen, S., Blattner, M., Lühmann, D., Tinnermann, A., Scherer, M., & Büchel, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4732 · Cited by 33
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
Lacroix, C., Salvo, F., Gras‐Champel, V., et al. (2021) · Therapies · doi:10.1016/j.therap.2021.05.003 · Cited by 28
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
Fabris, M., Marchi, G. D., Domenis, R., Caponnetto, F., Guella, S., Secco, C. D., Cabas, N., Vita, S. D., Beltrami, A. P., Curcio, F., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102827 · Cited by 38
David, S. S. B., Shamir-Stein, N., Gez, S. B., Lerner, U., Rahamim‐Cohen, D., & Zohar, A. E. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108860 · Cited by 28
The Function of Immunoproteasomes—An Immunologists’ Perspective
van den Eshof, B. L., Medfai, L., Nolfi, E., Wawrzyniuk, M., & Sijts, A. J. A. M. (2021) · Cells · doi:10.3390/cells10123360 · Cited by 29
COVID-19 Research: Lessons from Non-Human Primate Models
Albrecht, L., Bishop, E., Jay, B., Lafoux, B., Minoves, M., & Passaes, C. (2021) · Vaccines · doi:10.3390/vaccines9080886 · Cited by 35
“Significant increase in IgG, NAb titers and spike-specific IFNγ producing cells were observed, especially after the second vaccination with 8 µg of CVnCoV, but not with 0.5 µg (suboptimal dose).”
BackgroundInfluentialComparing the dynamics of COVID-19 infection and mortality in the United States, India, and Brazil
James, N., Menzies, M., & Bondell, H. D. (2022) · Physica D Nonlinear Phenomena · doi:10.1016/j.physd.2022.133158 · Cited by 30
“Medical researchers have uncovered numerous means of treating infections [4, 5, 6, 7], culminating in the production of vaccines [8, 9].”
BackgroundA Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens
Upreti, S., & Samant, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03323-w · Cited by 32
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 33
Zivkovic, S. A., Gruener, G., & Narayanaswami, P. (2021) · Muscle & Nerve · doi:10.1002/mus.27179 · Cited by 27
Bouwmans, P., Messchendorp, A. L., Sanders, J., Hilbrands, L. B., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., ten Dam, M. A., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02680-3 · Cited by 27
Grant, M. D., Bentley, K., Fielding, C. A., Hatfield, K. M., Ings, D. P., Harnum, D. O. A., Wang, E. C. Y., Stanton, R. J., & Holder, K. A. (2023) · JCI Insight · doi:10.1172/jci.insight.170681 · Cited by 31
Neuromuscular complications of coronavirus disease-19
Suh, J., & Amato, A. A. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000970 · Cited by 33
“GBS was not reported as an adverse event in the clinical trials for the two mRNA COVID-19 vaccines approved by the United States Food and Drug Administration [28,35].”
BackgroundAllergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
Robinson, L. B., Landman, A., Shenoy, E. S., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.05.031 · Cited by 28
Delirium triggered by COVID ‐19 vaccine in an elderly patient
Zavala‐Jonguitud, L. F., & Pérez‐García, C. C. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14163 · Cited by 28
RNA Viruses, Pandemics and Anticipatory Preparedness
García-Blanco, M. A., Ooi, E. E., & Sessions, O. M. (2022) · Viruses · doi:10.3390/v14102176 · Cited by 28
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
Ponticelli, D., Madotto, F., Conti, S., Antonazzo, I. C., Vitale, A., Ragione, G. D., Romano, M. L., Borrelli, M., Schiavone, B., Polosa, R., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02857-y · Cited by 29
Nakahara, T., Iwabuchi, Y., Miyazawa, R., Tonda, K., Shiga, T., Strausś, H. W., Antoniades, C. A., Narula, J., & Jinzaki, M. (2023) · Radiology · doi:10.1148/radiol.230743 · Cited by 31
Yang, X. S., Chen, M., Cao, L., & Zhao, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2270194 · Cited by 29
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola, M. S., Malandrakis, P., Gianniou, D. D., Kastritis, E., Trougakos, I. P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020338 · Cited by 29
Ricardo, J. W., & Lipner, S. R. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.09.009 · Cited by 29
“In phase 3 trials, the vaccine, which uses an mRNA platform encoding the spike glycoprotein of SARS-CoV-2, confers 52% protection against COVID-19 12 days following the first dose and 95% protection after the second dose, if administered 3 to 4 weeks apart in individuals without previous SARS-CoV-2 infection.(1) Altho…”
Cheng, X., Liu, S., Sun, J., Liu, L., Ma, X., Li, J., Fan, B., Chen, Y., Zhao, Y., Liu, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202310886 · Cited by 32
Medhat, R., El-Lababidi, R. M., Abdelsalam, M., & Nusair, A. R. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.001 · Cited by 27
Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
Tomar, P. P. S., Krugliak, M., & Arkin, I. T. (2021) · Viruses · doi:10.3390/v13030532 · Cited by 27
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer
Cai, J., Liu, Z., Chen, S., Zhang, J., Li, H., Wang, X., Feng, Y., Wang, S., Li, X., Li, Y., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00625-8 · Cited by 41
Vaccination Disparity: Quantifying Racial Inequity in COVID-19 Vaccine Administration in Maryland
Cardona, S., Felipe, N., Fischer, K. R., Sehgal, N. J., & Schwartz, B. E. (2021) · Journal of Urban Health · doi:10.1007/s11524-021-00551-0 · Cited by 28
“We assumed a zero percent mortality from COVID-19 among the population successfully vaccinated [5, 6].”
BackgroundChen, Z., Ren, A., Li, Y., Shu, J., Wu, J., Huang, H., Wang, J., Hu, Y., & Mei, H. (2025) · British Journal of Haematology · doi:10.1111/bjh.19988 · Cited by 36
Kemlin, D., Gemander, N., Depickère, S., Olislagers, V., Georges, D., Waegemans, A., Pannus, P., Lemy, A., Goossens, M. E., Desombere, I., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.02.015 · Cited by 36
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
Güven, D. C., Şahin, T. K., Kılıçkap, S., & Uckun, F. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759108 · Cited by 27
Cutaneous reactions after COVID ‐19 vaccination in Turkey: A multicenter study
Cebeci, F., Erdoğan, S. S., Aktaş, N. D., Albayrak, H., Türkmen, D., Borlu, M., Arıca, D. A., Demirbaş, A., Akbayrak, A., Ekinci, A. P., et al. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15209 · Cited by 28
Legumain In Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis
Liu, Z., Chen, C., Zhang, Y., Ji, F., Liu, H., Du, H., Guo, Y., Dong, X., Yang, Z., Han, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417831 · Cited by 31
Hu, X., Wang, H.-Y., Otero, C. E., Jenks, J. A., & Permar, S. R. (2022) · Annual Review of Virology · doi:10.1146/annurev-virology-100220-010653 · Cited by 34
Caliskan, I., Buluş, E., Afşar, N., & Altıntaş, A. (2022) · The Neurologist · doi:10.1097/nrl.0000000000000420 · Cited by 28
Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased
Diebold, M., Locher, E., Boide, P., Enzler-Tschudy, A., Faivre, A., Fischer, I., Helmchen, B., Hopfer, H., Kim, M. J., Moll, S., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.021 · Cited by 30
“127 (85, 165) 162 (103, 276) 130 (104, 263) 86 (82, 173) 52 (37, 79) 31 (15, 52) 47 (15, 66) 67 (38, 75) 39 (36, 43) 34 (29, 39) 21 (20, 24) 25 (22, 28) 1 (1, 3) 1 (0, 3) 11 (5, 13) 8 (6, 11)”
Vaccinations, Mobility and COVID-19 Transmission
Guo, J., Deng, C. R., & Гу, Ф. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010097 · Cited by 32
Nojszewska, M., Kalinowska, A., Adamczyk-Sowa, M. H., Kułakowska, A., & Bartosik-Psujek, H. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0016 · Cited by 32
ABO Blood System and COVID-19 Susceptibility: Anti-A and Anti-B Antibodies Are the Key Points
Tamayo-Velasco, Á., Peñarrubia-Ponce, M. J., Álvarez, F. J., de la Fuente, I., González, S. P., & Andaluz‐Ojeda, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.882477 · Cited by 34
“Although vaccines are being encouraged to hinder the spread of this pandemic (4, 5), the pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not well understood.”
BackgroundLiu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26
Karbiener, M., Farcet, M. R., Schwaiger, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab482 · Cited by 28
“mRNA vaccines are now understood to induce SARS-CoV-2 neutralizing antibody levels that are several-fold more potent than following COVID-19 infection [2,3].”
BackgroundCutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review
Wollina, U., Chiriac, A. E., Kocić, H., Koch, A., & Brzeziński, P. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00876-0 · Cited by 31
Are COVID-19 vaccines safe for people with epilepsy? A cross-sectional study
Özdemir, H. N., Dere, B., Gökçay, F., & Gökçay, A. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05956-6 · Cited by 27
“Almost all participants’ local adverse events and systemic adverse events lasted less than 7 days, as the clinical trials and real-life studies stated [3, 5, 6].”
BackgroundResultInfluential
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.